Roche Holding Ltd · SIX:RO
Roche — Berenberg European Conference 2023
24 slides from Roche's conference presentation, Dec 7, 2023
Slide 1: Slide 1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Berenberg European Conference 2023
Berenberg European Conference 2023 Bruno Eschli | Head of Investor Relations London, 7 December 2023
Slide 4: Performance Update, Strategy and Outlook, Latest Pipeline Update
Performance Update Strategy and Outlook Latest pipeline Update
Slide 5: Our achievements
Our achievements Roche is continuously shifting the standard of care A legacy of patient and business …with a track record of establishing standard of care impact… across new therapeutic areas 16 Blockbuster drugs in 2022, up from 7 in 2012 #1 in neurology and hemophilia A1 First and only therapy Fi
Slide 6: YTD Sep 2023: Strong base business growth in both divisions
YTD Sep 2023: Strong base business growth in both divisions COVID-19 impact to reduce significantly by end of Q1 2024 Pharma Diagnostics Quarterly sales evolution 2022-2023 Quarterly sales evolution 2022-2023 % CER % CER +30% +30% +24% +20% +20% +11% +8% +9% +9% +7% +8% +7% +10% +7% +10% +4% +6% +4%
Slide 7: Young portfolio driving Pharma division growth momentum
Young portfolio driving Pharma division growth momentum Keeping historic launch momentum with two NMEs approved in 2023 CHFm % of Pharma Sales** 18,000 50% 16,000 42% 14,000 12,000 34% 10,000 23% 8,000 * 6,000 4,000 2,000 0 YTD Sep 2020 YTD Sep 2021 YTD Sep 2022 YTD Sep 2023 Cotellic Alecensa Tecent
Slide 8: FY 2023 sales guidance confirmed
FY 2023 sales guidance confirmed Sales drivers1 Pharma: Key products with strong growth and momentum from ongoing launches Diagnostics: Base business with good growth Group sales growth1 Low single digit decline COVID-19 sales for Diagnostics and Pharma expected to decline by roughly CHF -4.5bn AHR2
Slide 9: FY 2023 guidance confirmed
FY 2023 guidance confirmed Group sales growth1 Low single digit decline Core EPS growth1 Broadly in line with sales decline Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 9
Slide 10: Performance Update, Strategy and Outlook, Latest Pipeline Update
Performance Update Strategy and Outlook Latest pipeline Update
Slide 11: Number of pipeline assets in Phase I to III
Number of pipeline assets in Phase I to III Roche ranks #2 in total pipeline volume Total number of pipeline assets by phase*, # Phase III Phase II Phase I Peer1 12 39 50 101 11 36 51 98 Peer 2 11 56 29 96 Peer 3 15 29 36 80 Peer 4 11 30 36 77 Peer 5 19 25 27 71 Peer 6 9 29 25 63 Peer 7 5 26 30 61 P
Slide 12: Pipeline assets segmented by innovation potential
Pipeline assets segmented by innovation potential Roche ranks #2 in number of NMEs with first-in-class potential Total number of pipeline assets by innovation potential*, # First-in-class Fast-follower Others* Peer 1 45 11 15 36 17 45 Peer 2 34 7 20 Peer 3 33 23 21 Peer 4 29 7 60 Peer 5 25 10 14 Pee
Slide 13: Pipeline acceleration via partnering
Pipeline acceleration via partnering Deals of the past two years increasingly focused on clinical stage NMEs* Development stage Current Immunology Cardiovascular & Metabolism Oncology / Hematology Ophthalmology Positive proof of concept data at time of deal development stage *Table shows clinical st
Slide 14: Building blocks for future growth through 2030
Building blocks for future growth through 2030 Recent acquisitions adding significant upside potential Carmot Alnylam Therapeutics Oncology / Hematology partnership acquisition Neuroscience Ophthalmology Emerging assets from early Immunology pipeline and BD† CVM Telavant CT-388 / anti-IL6 mAb ASO Fa
Slide 15: Consensus outlook 2022-26
Consensus outlook 2022-26* Growth driven by our young on-market portfolio; potential pipeline up-side Biosimilar gap (22-26) Consensus sales growth (22-26) Potential up-side3 Post-HY 2023 consensus survey Ronapreve 1.7 bn Vabysmo 4.3 bn Tecentriq 1.7 bn Additional up-side by late-stage Lucentis 1.0
Slide 16: Performance Update, Strategy and Outlook, Latest Pipeline Update
Performance Update Strategy and Outlook Latest pipeline Update
Slide 17: 2023: Key late-stage newsflow
2023: Key late-stage newsflow* Compound Indication Milestone Hemlibra Moderate hemophilia A EU approval Polivy + R-CHP 1L DLBCL US approval Vabysmo RVO US approval/EU filing EU filing Regulatory Tecentriq Subcutaneous administration US approval/EU filing US 2024 / EU filing Columvi (glofitamab) 3L+
Slide 18: Alecensa: Unprecedented Ph III results in adjuvant ALK+ NSCLC
Alecensa: Unprecedented Ph III results in adjuvant ALK+ NSCLC Ph III (HORIZON-01) in unresectable NSCLC ongoing Ph III (ALINA) Alecensa results in adjuvant ALK+ NSCLC Disease-free survival (DFS) • Ph III (ALINA) met primary endpoint of DFS with a HR of 0.24 • First-in-class global filing ongoing; US
Slide 19: Inavolisib in PI3K-mutant breast cancer
Inavolisib in PI3K-mutant breast cancer Positive Ph III (INAVO120) results; H2H trial vs. alpelisib initiated Potential best-in-class PI3Kα inh Potential for differentiated safety, efficacy, and combinability Potency/selectivity (inavolisib vs. alpelisib) Ph I dose escalation and expansion cohort: C
Slide 20: Growing portfolio in breast cancer: Expanding beyond HER2+ BC
Growing portfolio in breast cancer: Expanding beyond HER2+ BC Breast cancer cases by subtype1 Ph III clinical development overview Novel mechanisms and technologies Ph I Ph II Ph III On-market portfolio Pipeline molecules Giredestrant + palbociclib (perservERA) in 1L ER+/HER2- mBC giredestrant Gired
Slide 21: Trontinemab in Alzheimer's disease
Trontinemab in Alzheimer’s disease First dose finding data for BrainshuttleTM anti-Aβ presented at CTAD Trontinemab Trontinemab is differentiated from conventional anti-Aβ mAbs and (BrainshuttleTM anti-Aβ Ab) other brain delivery technologies Blood BBB Brain tissue Homogeneous brain Inverted TfR1 bi
Slide 22: Important launches ahead in Diagnostics
Important launches ahead in Diagnostics Diagnostics to deliver mid to high single digit growth in coming years Continuous glucose Next generation Core & Molecular Lab Mass spectrometry monitoring (CGM) sequencing (NGS) • Menu expansion driving growth, • First fully integrated and • Subcutaneously in
Slide 23: Upcoming Roche IR events
Upcoming Roche IR events Updates on Neuroscience, Digitalization, ASH presentations and Diagnostics Neuroscience Update Digitalization Day ASH Update Diagnostics Day Oct 30 Nov 29 Dec 12 May 22, 2024 Virtual event Virtual event Virtual event London & virtual • Covering ECTRIMS & CTAD data: • Present
Slide 24: Slide 24